The role of JAK2 abnormalities in hematologic neoplasms.

Clicks: 329
ID: 63815
2009
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
In 2005, an activating mutation in the Janus kinase 2 (JAK2) was identified in a significant proportion of patients with myeloproliferative neoplasms, mainly polycythemia vera, essential thrombocythemia and primary myelofibrosis. Many types of mutations in the JAK-STAT pathway have been identified, the majority are related to JAK2. Currently JAK2 mutations are important in the area of diagnosis of myeloid neoplasms, but its role beyond the confirmation of clonality is growing and widening our knowledge about these disorders. In addition to that, clinical trials to target JAK2-STAT pathway will widen our knowledge and hopefully will offer more therapeutic options. In this review, we will discuss the role of JAK2 abnormalities in the pathogenesis, diagnosis, classification, severity and management of hematologic neoplasms.
Reference Key
alabdulaali2009thehematology Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Alabdulaali, Mohammed Khalid;
Journal hematology reports
Year 2009
DOI
DOI not found
URL
http://www.pagepress.org/journals/index.php/hr/article/view/176
Keywords
chemistry Medicine (General) Diseases of the blood and blood-forming organs Other systems of medicine neoplasms. tumors. oncology. including cancer and carcinogens internal medicine

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.